A New Frontier in Heart Health: TRiCares' Topaz Valve Trial Approved

MINNEAPOLIS, MN – April 07, 2026 – A groundbreaking medical device designed to treat a common but undertreated heart condition has cleared a major regulatory hurdle, offering potential new hope to millions of patients worldwide. TRiCares SAS announced today that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a pivotal clinical trial for its Topaz Transcatheter Tricuspid Valve Replacement (TTVR) system.

The approval allows the company to launch the TRICURE US pivotal trial, a large-scale study that will evaluate the safety and effectiveness of the minimally invasive Topaz system. This marks a critical step toward potential U.S. market approval for a device aimed at patients with severe tricuspid regurgitation who are too high-risk for open-heart surgery.

The Silent Epidemic of Tricuspid Regurgitation

Tricuspid regurgitation (TR), a condition where the heart's tricuspid valve fails to close properly, causes blood to leak backward into the right atrium. While often overlooked, severe TR is far from benign. It is linked to debilitating symptoms like fatigue, fluid retention, and shortness of breath, ultimately leading to right-sided heart failure and a significantly increased risk of mortality.

An estimated 70 million people globally, including about 1.5 million in the United States, suffer from this condition. It disproportionately affects older adults and women, who are up to four times more likely to be diagnosed than men. Despite its prevalence and severe consequences, TR remains profoundly undertreated. Historically, treatment options have been limited and often inadequate. Medical management with diuretics can help manage symptoms but does not address the underlying valve issue or improve survival.

The only definitive treatment has been open-heart surgery to repair or replace the valve, but this carries substantial risks. Consequently, many patients, particularly the elderly and those with other health complications, are deemed ineligible for the procedure. Industry data suggests that fewer than 0.5% of patients in the U.S. with severe TR receive surgical treatment, creating a vast unmet medical need for safer, less invasive alternatives.

A Novel Solution for a Complex Problem

The Topaz system from TRiCares is engineered specifically to address this treatment gap. It is a transcatheter heart valve replacement, meaning it can be delivered to the heart through catheters inserted into veins in the leg and neck, avoiding the trauma of open-heart surgery.

What sets Topaz apart is its unique dual-stent design, tailored for the complex and delicate anatomy of the tricuspid valve. It features a flexible outer stent with a low radial force that conforms to the heart's natural movement and the valve's irregular shape, which is intended to minimize the risk of damaging the heart's electrical conduction system—a common complication with other valve implants that can necessitate a permanent pacemaker. A second, rigid inner stent houses the valve itself, ensuring its circular shape and long-term functional integrity.

Early clinical data has been highly encouraging. A first-in-human study published in the journal EuroIntervention in late 2025 demonstrated remarkable results. Among the 20 patients studied, the Topaz system achieved a 100% success rate in reducing TR to mild or trace levels. The average procedure time was a swift 35 minutes, and critically, no patients required a permanent pacemaker as a result of the device implant. These results suggest the procedure is not only effective but also maintains a strong safety profile.

The Path to US Market Approval

The FDA's IDE approval is a testament to the strength of this early clinical evidence. It allows TRiCares to move forward with its TRICURE US pivotal trial, a randomized study that will enroll patients at up to 75 investigative sites across the United States, Canada, and Europe. This rigorous trial is the final major step required to gather the comprehensive safety and effectiveness data needed for full FDA market approval and subsequent commercialization in the U.S.

"Receiving FDA approval for our US IDE pivotal trial marks a significant milestone for TRiCares and, most importantly, for the many patients living with tricuspid regurgitation who urgently need improved treatment options," said Ahmed Elmouelhi, President & CEO of TRiCares, in a statement. "This approval allows us to approach our investigator sites and prepare for first patient enrollments, bringing us closer to realizing our ambition of making Topaz the standard of care for patients across the US."

Leading cardiologists involved in the upcoming trial share this optimism. Dr. Pradeep Yadav of the Piedmont Heart Institute and Co-Principal Investigator of the study commented on the device's potential. “TTVR is rapidly emerging as a preferred treatment option for symptomatic patients with TR. We have been highly impressed with Topaz’s next-generation design, which enables streamlined implantation while maintaining a strong focus on safety and adaptability across complex patient anatomies,” he noted.

Dr. Neil Fam, Director of the Structural Heart Program at St. Michael’s Hospital in Toronto and the trial's other Co-Principal Investigator, added, "This IDE approval is an important step forward in combating structural heart disease. The early clinical data... have been encouraging and have significantly reduced the burden of procedural imaging."

A Competitive and Expanding Landscape

TRiCares enters a dynamic and rapidly growing market. The global TTVR market is projected to skyrocket from approximately $300 million in 2025 to nearly $3.7 billion by 2035. Currently, the only FDA-approved TTVR device in the U.S. is the EVOQUE valve from Edwards Lifesciences, giving it a first-mover advantage. Other companies, like Abbott, offer a valve repair system called TriClip, which addresses the problem without a full replacement.

However, TRiCares' Topaz system is positioned to be a strong competitor, with its focus on procedural simplicity and, most notably, its low associated pacemaker rate. The strong financial backing for TRiCares, including a recent $50 million Series D financing round from a strategic investor, underscores the high level of confidence in the technology's potential to capture a significant share of this emerging market. As the TRICURE US pivotal trial gets underway, the medical community will be watching closely, hopeful that this innovative device will soon become a widely available tool to transform the prognosis for millions of patients suffering from the silent burden of tricuspid regurgitation.